deltatrials
Completed PHASE3 NCT00002596

Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors

RANDOMIZED MULTIINSTITUTIONAL PHASE III TRIAL OF BEP AND HIGH DOSE CHEMOTHERAPY VERSUS BEP ALONE IN PREVIOUSLY UNTREATED PATIENTS WITH POOR RISK GERM CELL TUMORS

Sponsor: Cancer and Leukemia Group B

Updated 7 times since 2017 Last updated: Jun 25, 2013 Started: Sep 30, 1994 Completion: Jul 31, 2006

A PHASE3 clinical study on Childhood Germ Cell Tumor and Extragonadal Germ Cell Tumor, this trial is completed. The trial is conducted by Cancer and Leukemia Group B and has accumulated 7 data snapshots since 1994. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

7 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. May 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — May 2023 [monthly]

    Completed PHASE3

Show 2 earlier versions
  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Sep 1994

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cancer and Leukemia Group B
  • Eastern Cooperative Oncology Group
  • Memorial Sloan Kettering Cancer Center
  • National Cancer Institute (NCI)
  • SWOG Cancer Research Network
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States, Amarillo, United States, Ann Arbor, United States, Anniston, United States, Asheville, United States, Baltimore, United States, Bennington, United States, Boise, United States, Boston, United States, Buffalo, United States and 101 more location s